Cerulean Pharma Inc. (DARE) Reaches New 12-Month Low at $2.76
Cerulean Pharma Inc. (NASDAQ:DARE) shares hit a new 52-week low during trading on Thursday . The company traded as low as $2.76 and last traded at $2.63, with a volume of 75,953 shares traded. The stock had previously closed at $3.25.
Separately, ValuEngine upgraded Cerulean Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, July 22nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $2.55.
The firm’s 50 day moving average is $5.12 and its 200-day moving average is $7.85. The firm’s market cap is $7.63 million.
COPYRIGHT VIOLATION NOTICE: “Cerulean Pharma Inc. (DARE) Reaches New 12-Month Low at $2.76” was reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.dailypolitical.com/2017/08/10/cerulean-pharma-inc-dare-reaches-new-12-month-low-at-2-76.html.
Cerulean Pharma Company Profile
Dare Bioscience, Inc, formerly Cerulean Pharma Inc, is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse.
Receive News & Ratings for Cerulean Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerulean Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.